

PERFORMANCE DATA SHEET

2320

For maximal recovery of contents
please quick spin vial before opening

Human CD155(PVR)-muIg Fusion Protein*

CATALOG#: 555-820 (Preservative-free)

QUANTITY: 25 µg

CONCENTRATION: 0.5 mg/ml

Molecular Structure: A soluble molecule consisting of the extracellular domain of mature human CD155 fused to murine IgG2a Fc. Mature CD155(EC) (316aa):

**dvvvqaptqvpgflgdsvtlpcylqvpnmvthvsqiltwarhgessmavfhqtqgpsysekrlefvaarlgaelnaslrnfmglrvedegnytdlvtfpqgsrsvdiwlrvlakpqntaevqkvltgepvpma
revstggrppaqitwhsdlgmpntsqvpgflsgvtvtlswilvpsqvdgknvtckvehesfekpqltlnltvyyppesvisgydnwylgqneatftcdarsnpeptgynwsttmglppfavaqgaqlirp
dkpintllcnvtnalgarqaeltvqykegppsehsgetha**

Linking amino acids (2aa): **tr**

Murine IgG2aFc (233aa):

**eprgptlkpcppckcpapnllggpsvffppkikdvlmislspivtcvvdvseddpdvqiswfvnnevhtaqtqthredynstlrsvsalpiqhqdwmmsgkefkckvnmkdlpapiertiskpkgsrapqvy
vlpppeemtkkqvltcmvtdfimpediyvewtngkteleynktepvlidsdgsyfmysklrveknwvrrnsyscvvhgelnhhttkksirtpgk**

Predicted nonglycosylated monomeric weight: 61kd. .

Transfectant Cell Line: CHO

INFORMATION: Human CD155 (Polio Virus Receptor, PVR, Necl-5) is a 70 kd type I Ig superfamily molecule (1). It is involved in formation of intracellular junctions between epithelial cells. Its ligands include CD226(DNAM-1), and CD96(TACTILE). CD155 expression by tumor has been shown to be upregulated by Nitric Oxide(2). High CD155 expression has recently been exploited to use engineered poliovirus to treat glioblastoma. (3)

References: 1) Medelsohn CL, Racaniello VR, et al. (1989) *Cell* **56**(5): 855-65. 2) C Fionda, M Cippitelli, et al. (2015) *BMC Cancer* **15**(1):17 PMID 25609078. 3) Gromeier M, Bigner D, et al. (2014) *Neuro-Oncology* **16**(supp3): iii41.

STORAGE CONDITIONS: Store at 2 - 5°C. Open under aseptic conditions. Freeze/Thawing is not recommended.

PRODUCT STABILITY: Product should retain activity for at least 6 months after shipping date when stored as recommended. Ship Date: _____

BUFFER: 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl.

PRODUCTION: Human CD155-muIg fusion protein was purified from (low FBS containing) tissue culture supernatant of CHO transfectants using Protein A and size exclusion chromatography. Product was 0.2µ sterile filtered and vialled under aseptic conditions.

PERFORMANCE: Human CD155-muIg is reactive in EIA utilizing GAM capture and detection with anti-CD155 mAb. N-terminal sequencing was as predicted: DVVVQ.

CD155-muIg was tested for FACS binding to 3 day PHA-stimulated human PBMC. Five x 10⁵ cells per tube were washed and pre incubated 10 minutes with 300ug/ml human Ig (to reduce nonspecific binding) after which they were incubated 45 minutes on ice with 80 ul of CD155-muIg at 10 µg/ml. Cells were then washed twice and incubated with 2° detector Goat anti-Mouse/FITC (Catalog #232-011), after which they were washed three times, fixed and analyzed by FACS using a lymphoid gate. Cells stained positive with a mean shift of 0.59 log₁₀ fluorescent units when compared to background.

*Research use only. Not for use in Diagnostic procedures.

Binding of CD155-muIg with GAM/FITC to stimulated human PBL

